— medmix at a glance — Our key figures
Our key figures
Our revenue was CHF 250.6 million, an increase of 9.8% (10.2% currency-adjusted, all organic), compared to H1 2021. We delivered an adjusted EBITDA margin of 24.0% and free cash flow of CHF 14.3 million.
Share of revenue by market segment
H1 2022
Key figures
January 1 - June 30
|
millions of CHF |
|
2022 |
|
2021 |
|
Change in +/–% |
|
+/–% adjusted 1) |
|
+/–% organic 2) |
|
Revenue |
|
250.6 |
|
228.3 |
|
9.8 |
|
10.2 |
|
10.2 |
|
Gross profit |
|
97.9 |
|
91.8 |
|
6.6 |
|
|
|
|
|
Operating income (EBIT) |
|
31.3 |
|
31.3 |
|
–0.1 |
|
|
|
|
|
EBITDA |
|
56.5 |
|
56.9 |
|
–0.6 |
|
|
|
|
|
Adjusted EBITDA |
|
60.1 |
|
57.9 |
|
3.9 |
|
|
|
|
|
Adjusted EBITDA margin |
|
24.0% |
|
25.4% |
|
|
|
|
|
|
|
Net income attributable to shareholders of medmix Ltd |
|
23.8 |
|
22.7 |
|
4.6 |
|
|
|
|
|
Basic earnings per share (in CHF) |
|
0.58 |
|
0.55 |
|
5.3 |
|
|
|
|
|
Free cash flow (FCF) |
|
14.3 |
|
33.6 |
|
–57.5 |
|
|
|
|
|
Net debt as of June 30 / December 31 |
|
135.7 |
|
110.9 |
|
22.4 |
|
|
|
|
|
Employees (number of full-time equivalents) as of June 30 / December 31 |
|
2’101 |
|
2’036 |
|
3.2 |
|
|
|
|
1) Adjusted for currency effects.
2) Adjusted for acquisition and currency effects.
Our Key figures
revenue in H1 2022
adjusted EBITDA margin
free cash flow generated in H1 2022